(Osemitamab)Biosimilar Reference Antibody-GS40516 新品

货号：GS40516

Osemitamab (also known as TST001) is a humanized IgG1‑kappa monoclonal antibody that specifically targets claudin‑18.2 (CLDN18.2), a tight‑junction protein that is normally confined to gastric mucosal epithelial cells but becomes aberrantly exposed and overexpressed in a variety of solid tumors, including gastric, pancreatic, esophageal, and ovarian cancers. As an IgG1 isotype, it is engineered to engage immune effector functions such as antibody‑dependent cellular cytotoxicity (ADCC) and complement‑dependent cytotoxicity (CDC). By binding to CLDN18.2, osemitamab aims to induce tumor cell killing through these immune mechanisms and potentially disrupt tumor‑specific signaling. It is being developed as a potential therapeutic for CLDN18.2‑positive advanced solid tumors, with a focus on gastric/gastroesophageal junction adenocarcinoma.